Ethanol sclerotherapy for ovarian endometrioma –⁠ a systematic review and narrative synthesis

Czech version

Authors: O. Malchar; Radovan Pilka
Authors‘ workplace: Porodnicko-gynekologická klinika LF UP a FN Olomouc
Published in: Ceska Gynekol 2026; 91(3): 211-225
Category:
doi: https://doi.org/10.48095/cccg2026211

Overview

Objective: The aim of this review was to evaluate the efficacy and safety of ethanol sclerotherapy (EST) for ovarian endometriomas, regarding the risk of recurrence, impact on ovarian reserve, and comparison with laparoscopic cystectomy. Additionally, we evaluated whether the available studies assessed the impact of this method on the patients’ quality of life using validated questionnaires. Methods: A total of 27 studies (2009–2025; N = 1,936) were included, consisting of two randomized controlled trials (RCTs) and 25 observational studies. Risk of bias was assessed using the Cochrane RoB 2 and ROBINS-I tools. The primary outcomes were recurrence rate and quality of life; the secondary outcome was the change in anti-Müllerian hormone (AMH) levels. Results: Recurrence rate (0–48.6%) varied according to follow-up duration and treatment technique. Data suggest a benefit of the retention protocol (exposure ≥ 10 minutes) compared to simple irrigation. In the single RCT comparing EST and cystectomy, no significant difference in recurrence was found after 12 months (48.6 vs. 42.9%). Although surgery resulted in a decline in AMH levels, these remained largely stable following sclerotherapy (reported in 15 studies). No study evaluated quality of life using validated tools. The quality of evidence was limited by the predominance of observational studies with a risk of bias. Conclusion: EST represents a promising alternative to surgery, with a more favorable impact on ovarian reserve. The efficacy of recurrence prevention is variable depending on the duration of ethanol exposure. Given the methodological limitations and absence of quality of life data, findings must be interpreted with caution. Further RCTs, including quality of life assessment, are necessary to confirm clinical benefit.

Keywords:

Endometriosis – sclerotherapy – Ethanol – recurrence – laparoscopy – anti-Müllerian hormone – ovarian reserve – ovarian endometrioma

Sources

1. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med 2020; 382 (13): 1244–1256. doi: 10.1056/NEJMra1810764.

2. Becker CM, Bokor A, Heikinheimo O et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022; 2022 (2): hoac009. doi: 10.1093/hropen/ hoac009.

3. Muzii L, Di Tucci C, Di Feliciantonio M et al. Management of endometriomas. Semin Reprod Med 2017; 35 (1): 25–30. doi: 10.1055/s-00 36-1597120.

4. Vercellini P, Viganò P, Somigliana E et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2014; 10 (5): 261–275. doi: 10.1038/nrendo.2013.255.

5. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97 (9): 3146–3154. doi: 10.1210/jc.2012-1558.

6. Younis JS, Shapso N, Fleming R et al. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis. Hum Reprod Update 2019; 25 (3): 375–391. doi: 10.1093/humupd/dmy049.

7. Cohen A, Almog B, Tulandi T. Sclerotherapy for ovarian endometriomas: a systematic review and meta-analysis. Fertil Steril 2017; 108 (1): 117–124. doi: 10.1016/j.fertnstert.2017.05.015.

8. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. doi: 10.1136/bmj.n71.

9. Sterne JA, Hernán MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919. doi: 10.1136/bmj.i4919.

10. Sterne JA, Savović J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898. doi: 10.1136/bmj.14898.

11. Rabattu A, Swierkowski-Blanchard N, Paillusson B et al. Ethanol sclerotherapy of endometriomas prior to IVF/ICSI improves progressive pregnancy and live birth rate. J Gynecol Obstet Hum Reprod 2024; 53 (10): 102835. doi: 10.1016/j.jogoh.2024.102835.

12. De Cicco Nardone A, Carfagna P, De Cicco Nardone C et al. Laparoscopic ethanol sclerotherapy for ovarian endometriomas: preliminary results. J Minim Invasive Gynecol 2020; 27 (6): 1331–1336. doi: 10.1016/j.jmig.2019.09.792.

13. Yazbeck C, Madelenat P, Ayel JP et al. Ethanol sclerotherapy: a treatment option for ovarian endometriomas before ovarian stimulation. Reprod Biomed Online 2009; 19 (1): 121–125. doi: 10.1016/s1472-6483 (10) 60055-7.

14. Anvari Aliabad R, Ghasemzadeh A, Hamdi K et al. Investigating the efficacy of ultrasound-guided ethanol retention technique for endometrioma sclerotherapy and its effect on pro-inflammatory cytokine levels: a single-arm clinical trial. Clinics (Sao Paolo) 2023; 78 : 100224. doi: 10.1016/j.clinsp.2023.100224.

15. Lee JK, Ahn SH, Kim HI et al. Therapeutic efficacy of catheter-directed ethanol sclerotherapy and its impact on ovarian reserve in patients with ovarian endometrioma at risk of decreased ovarian reserve: a preliminary study. J Minim Invasive Gynecol 2022; 29 (2): 317–323. doi: 10.1016/j.jmig.2021.08.018.

16. Wang B, Zhu X, Sun X et al. Analysis of the effects of cystic cavity flushing with lidocaine during ultrasound-guided anhydrous ethanol sclerotherapy in the treatment of ovarian endometrioma. Quant Imaging Med Surg 2025; 15 (5): 4135–4145. doi: 10.21037/qims-24-2072.

17. Aflatoonian A, Rahmani E, Rahsepar M. Assessing the efficacy of aspiration and ethanol injection in recurrent endometrioma before IVF cycle: a randomized clinical trial. Iran J Reprod Med 2013; 11 (3): 179–184.

18. Martinez-Garcia JM, Candas B, Suarez-Salvador E et al. Comparing the effects of alcohol sclerotherapy with those of surgery on anti-Mullerian hormone and ovarian reserve after endometrioma treatment. A prospective multicenter pilot cohort study. Eur J Obstet Gynecol Reprod Biol 2021; 259 : 60–66. doi: 10.1016/j.ejogrb.2021.01.027.

19. Lee JH, Yoon J, Lee CH et al. Long-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma. J Vasc Interv Radiol 2025; 31 (3): 249–252. doi: 10.4274/dir.2024.242874.

20. Alborzi S, Askary E, Keramati P et al. Assisted reproductive technique outcomes in patients with endometrioma undergoing sclerotherapy vs laparoscopic cystectomy: prospective cross-sectional study. Reprod Med Biol 2021; 20 (3): 313–320. doi: 10.1002/rmb2.12386.

21. Garcia-Tejedor A, Martinez-Garcia JM, Candas B, et al. Ethanol sclerotherapy versus laparoscopic surgery for endometrioma treatment: a prospective, multicenter, cohort pilot study. J Minim Invasive Gynecol 2020; 27 (5): 1133–1140. doi: 10.1016/j.jmig.2019.08.036.

22. Lee JK, Han K, Choi E et al. Effect of catheter-directed ethanol sclerotherapy on ovarian reserve in patients with recurrent endometrioma: comparative analysis with primary endometriosis. Eur Radiol 2024; 34 (5): 3298–3308. doi: 10.1007/s00330-023-10320-z.

23. Miquel L, Preaubert L, Gnisci A et al. Endometrioma ethanol sclerotherapy could increase IVF live birth rate in women with moderate-severe endometriosis. PloS One 2020; 15 (9): e0239846. doi: 10.1371/journal.pone.0239846.

24. Tehrani HG, Tavakoli R, Hashemi M et al. Ethanol sclerotherapy versus laparoscopic surgery in management of ovarian endometrioma: a randomized clinical trial. Arch Acad Emerg Med 2022; 10 (1): e55. doi: 10.22037/aaem.v10i1.1636.

25. Mohtashami S, Jabarpour M, Aleyasin A et al. Efficacy of ethanol sclerotherapy versus laparoscopic excision in the treatment of ovarian endometrioma. J Obstet Gynaecol India 2024; 74 (1): 60–66. doi: 10.1007/s13224-023-01840-1.

26. Hsieh CL, Shiau CS, Lo LM et al. Effectiveness of ultrasound-guided aspiration and sclerotherapy with 95% ethanol for treatment of recurrent ovarian endometriomas. Fertil Steril 2009; 91 (6): 709–2713. doi: 10.1016/j.fertnstert.2008.03.056.

27. Chang MY, Hsieh CL, Shiau CS et al. Ultra--sound-guided aspiration and ethanol sclerotherapy (EST) for treatment of cyst recurrence in patients after previous endometriosis surgery: analysis of influencing factors using a decision tree. J Minim Invasive Gynecol 2013; 20 (5): 595–603. doi: 10.1016/j.jmig.2013.03.004.

28. Aflatoonian A, Tabibnejad N. Aspiration versus retention ultrasound-guided ethanol sclerotherapy for treating endometrioma: a retrospective cross-sectional study. Int J Reprod Biomed 2020; 18 (11): 935–942. doi: 10.18502/ijrm.v13i11.7960.

29. Han K, Seo SK, Kim MD et al. Catheter-directed sclerotherapy for ovarian endometrioma: short-term outcomes. Radiology 2018; 289 (3): 854–859. doi: 10.1148/radiol.2018180606.

30. Zeng CH, Cao CW, Shin JH et al. Safety and clinical outcomes of two-session catheter-directed sclerotherapy using ethanol for endometrioma. Cardiovasc Intervent Radiol 2024; 47 (7): 901–909. doi: 10.1007/s00270-024-03700-5.

31. Miquel L, Liotta J, Pivano A et al. Ethanol endometrioma sclerotherapy: safety through 8 years of experience. Hum Reprod 2024; 39 (4): 733–741. doi: 10.1093/humrep/deae014.

32. Koo JH, Lee I, Han K et al. Comparison of the therapeutic efficacy and ovarian reserve between catheter-directed sclerotherapy and surgical excision for ovarian endometrioma. Eur Radiol 2021; 31 (1): 543–548. doi: 10.1007/s00330-020-071111-1.

33. Vaduva CC, Dira L, Carp-Veliscu A et al. Ovarian reserve after treatment of ovarian endometriomas by ethanolic sclerotherapy compared to surgical treatment. Eur Rev Med Pharmacol Sci 2023; 27 (12): 5575–5582. doi: 10.26355/eurrev_202306_32795.

34. Sadullayev A, Medvediev M. Comparison of the effect on the ovarian reserve of modern methods of treatment of endometrioid cysts. J Obstet Gynaecol Can 2022; 44 (8): 908–914. doi: 10.1016/j.jogc.2022.04.006.

35. Crestani A, Merlot B, Goualard PH et al. Laparoscopic sclerotherapy for ovarian endometriomas during surgery for deep endometriosis: outcomes of a 134-patient cohort. Int J Gynaecol Obstet 2025; 171 (1): 431–437. doi: 10.1002/ijgo.70201.

36. Ghasemi F, Kashani L, Moini A et al. Assisted reproductive technology outcomes after ethanol sclerotherapy in poor responder patients with endometriomas: a before-after clinical trial. J Reprod Infertil 2024; 25 (3): 224–230. doi: 10.18502/jri.v25i3.17017.

37. Begum MR, Ehsan M, Ehsan N et al. Sclerotherapy with ethanol: an effective and safe alternative to potentially complex surgical treatment of recurrent ovarian endometrioma. J SAFOG 2015; 7 (2): 97–101. doi: 10.5005/jp-journals-10006-1335.